These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 11100963)
1. Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy. Choo-Kang LR; Zeitlin PL Curr Opin Pulm Med; 2000 Nov; 6(6):521-9. PubMed ID: 11100963 [TBL] [Abstract][Full Text] [Related]
2. Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapy. Kerem E Pediatr Pulmonol; 2005 Sep; 40(3):183-96. PubMed ID: 15880796 [TBL] [Abstract][Full Text] [Related]
3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419 [TBL] [Abstract][Full Text] [Related]
4. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Sloane PA; Rowe SM Curr Opin Pulm Med; 2010 Nov; 16(6):591-7. PubMed ID: 20829696 [TBL] [Abstract][Full Text] [Related]
5. Use of protein repair therapy in the treatment of cystic fibrosis. Rubenstein RC; Zeitlin PL Curr Opin Pediatr; 1998 Jun; 10(3):250-5. PubMed ID: 9716885 [TBL] [Abstract][Full Text] [Related]
6. [Functional characterization of naturally occurring CFTR mutants: interest for cystic fibrosis]. Romey MC Ann Biol Clin (Paris); 2006; 64(5):429-37. PubMed ID: 17040873 [TBL] [Abstract][Full Text] [Related]
7. Repairing the basic defect in cystic fibrosis - one approach is not enough. Farinha CM; Matos P FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of cystic fibrosis treatment. Carter SC; McKone EF Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265 [TBL] [Abstract][Full Text] [Related]
11. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies. Amaral MD Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334 [TBL] [Abstract][Full Text] [Related]
12. A new era of personalized medicine for cystic fibrosis - at last! Quon BS; Wilcox PG Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544 [TBL] [Abstract][Full Text] [Related]